Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • M Offline
    M Offline
    Mogan
    wrote on sidst redigeret af
    #968

    God morgen 😉

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #969

      Tak bibob.

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bibob
        wrote on sidst redigeret af
        #970

        Tak Sukker. Selvfølgelig. 😉

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #971

          Phase 3 Amivantamab trial,
          1000 participants!!

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #972

            A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) https://www.clinicaltrials.gov/ct2/show/NCT04487080?recrs=ab&cond=Lung+Cancer&sfpd_s=07%2F14%2F2020&sfpd_d=14&sel_rss=new14

            1 Reply Last reply
            0
            • M Offline
              M Offline
              Mcjean
              wrote on sidst redigeret af
              #973

              Wouw thats a lot, isnt it?

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #974

                Yes it is. They perhaps need power to show better effect. What do Osimertinib have in revenue ?

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #975

                  Tagrisso: $982M (+56%) Q120

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #976

                    Novartis also with a new trial , for patients that want to switch to Ofa from another CD20 https://www.clinicaltrials.gov/ct2/show/NCT04486716?term=NCT04486716&draw=2&rank=1

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #977

                      Lidt mere om Lazertinib https://www.fiercebiotech.com/biotech/janssen-taps-south-korea-s-yuhan-for-tagrisso-rival Gode data og baren er sat højt.

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #978

                        Barren skulle der stå 😉

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          Joakim_Von_And
                          wrote on sidst redigeret af
                          #979

                          De stoffer I nævner Amivantamab, Lazertinib..Hvem har de forbindelse til ? Kan ikke finde ud af om det er godt eller skidt for genmab.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #980

                            Amivantamab (JNJ-61186372) is a bispecific antibody that targets EGFR and cMet, two validated cancer targets. The two antibodies used to create amivantamab (JNJ-61186372) were both created by Genmab.

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #981

                              God morgen. 🙂

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bibob
                                wrote on sidst redigeret af
                                #982

                                God morgen. 🙂

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #983

                                  Der må falde en milestone når fase III med amivantamab starter op - ligeledes når første registreringsansøgning indsendes sidt på året. Bliver spændende at se hvor backloaded disse aftaler er

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #984

                                    Nogen der husker strukturen på en lignende aftale. Den er selvfølgelig backloaded i høj grad, men må også være ret simpel, da man jo for mange af programmerne ikke kendte targets og dermed mulige indikationer. Så mon den alene går på første indikation der kommer hele vejen, for de milestones det gælder klinisk udvikling og registrering. Gætter på at mindst halvdelen af milestonepakken er salgsmilestones

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      BioShare
                                      wrote on sidst redigeret af
                                      #985

                                      Gik alt, alt for langsomt med at få indrullet patienterne i det ACCORD-studie....trist. I stedet startes et nye forsøg op "overseas"...

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        BioShare
                                        wrote on sidst redigeret af
                                        #986

                                        Sorry, forkert chat 😞

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #987

                                          from 2019 : Janssen DuoBody Collaboration
                                          In July 2012, we entered into a collaboration with Janssen to create and develop bispecific antibodies using our DuoBody platform. Under this agreement, Janssen received an exclusive worldwide license to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations. We recorded an upfront payment of $3.5 million from Janssen and will potentially be entitled to milestone and

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger